Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trialMariaelena Pierobon, Stephen P. Anthony, Elisa Baldelli et al.|Molecular Oncology|2021Cited by 14
Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience.Mariaelena Pierobon, Stephen P. Anthony, Nicholas J. Robert et al.|Journal of Clinical Oncology|2018Cited by 4
Author response for "Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial"Mariaelena Pierobon, Stephen P. Anthony, Nicholas J. Robert et al.|Unknown|2021Cited by 0